Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19

J Card Fail. 2020 May;26(5):370. doi: 10.1016/j.cardfail.2020.04.013.
No abstract available

Publication types

  • Editorial

MeSH terms

  • American Heart Association
  • Angiotensin Receptor Antagonists / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Betacoronavirus* / drug effects
  • Betacoronavirus* / physiology
  • COVID-19
  • Comorbidity
  • Consensus
  • Coronavirus Infections* / epidemiology
  • Coronavirus Infections* / therapy
  • Heart Failure* / drug therapy
  • Heart Failure* / epidemiology
  • Humans
  • Pandemics*
  • Pneumonia, Viral* / epidemiology
  • Pneumonia, Viral* / therapy
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / physiology
  • Risk Assessment
  • SARS-CoV-2
  • Standard of Care
  • United States

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors